Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Seraph Pharmaceutical

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000860 102 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx102product presentations
G35generic molecules
DF10dosage-form groups
TA7therapeutic areas
PKR102current price records
REG71registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage95%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixSeraph PharmaceuticalShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/seraph-pharmaceuticalGenerated 10 Aug 2026Anti-infectives57 · 56%CNS & mental health28 · 27%Dermatology5 · 5%Gastrointestinal & hepatology5 · 5%Oncology & immunology4 · 4%Cardiovascular2 · 2%Other specialty1 · 1%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioSeraph PharmaceuticalDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/seraph-pharmaceuticalGenerated 10 Aug 2026102presentationsTablet48 · 47%Injection29 · 28%Cream7 · 7%Capsule6 · 6%Lotion3 · 3%Solution3 · 3%Other forms6 · 6%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionSeraph PharmaceuticalCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/seraph-pharmaceuticalGenerated 10 Aug 202697comparable productsBelow market median53 · 55%Near market median39 · 40%Above market median5 · 5%Company median price position-5.6%Lowest-price equivalents9Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsSeraph PharmaceuticalCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/seraph-pharmaceuticalGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,26 shared74% overlapPharmasol (Pvt) Ltd.26 shared74% overlapCCL Pharmaceuticals (Pvt.) Ltd.24 shared69% overlapBio-Labs(Pvt) Ltd23 shared66% overlapHigh-Q Pharmaceuticals23 shared66% overlapMediate Pharmaceutical Pvt Ltd22 shared63% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives57 products · 56%
CNS & mental health28 products · 27%
Dermatology5 products · 5%
Gastrointestinal & hepatology5 products · 5%
Oncology & immunology4 products · 4%
Cardiovascular2 products · 2%
Other specialty1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins19 products · 19%
Antipsychotics12 products · 12%
Antiepileptics11 products · 11%
Macrolide antibacterials8 products · 8%
Fluoroquinolone antibacterials6 products · 6%
Antifungals5 products · 5%
Antipsoriatic medicines5 products · 5%
Antiparasitic medicines5 products · 5%
Formulation footprint

Dosage forms

Tablet48 products
Injection29 products
Cream7 products
Capsule6 products
Lotion3 products
Solution3 products
Gel2 products
Suspension2 products
Infusion1 products
Ointment1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 DroncefCeftriaxone 12presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 LevaceLevetiracetam 9presentations 100 mg/mL, 250 mg, 500 mg · Injection, Solution, Tablet #3 OrisRisperidone 6presentations 1 mg, 2 mg, 3 mg, 4 mg · Tablet #4 CequelQuetiapine 5presentations 100 mg, 25 mg, 300 mg · Tablet #5 CartrialCalcipotriol 4presentations 0.005%, 0.05 mg, 0.05 mg/g · Cream #6 Zyban 150mg SRBupropion 4presentations 150 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median5355% of comparable products
Near market median39within ±5% of median
Above market median55% of comparable products
Lowest-price equivalents9ties included
Company median price position -5.6% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Zyban 300 mgBupropion · Sustained-release tablet · 2x10's PKR 47.07/tablet-47.2% vs market median Sthrin 5%Permethrin · Cream · 30gm PKR 2.48/g-36.5% vs market median Sephrix B 0.5 mgEntecavir · Tablet · 3x10's PKR 280.20/tablet-21.3% vs market median Actarin 20 mg/gMiconazole · Gel · 20 gm PKR 6.78/g-19.6% vs market median Icunem 1 gMeropenem · Injection · 1's PKR 3,188.94/vial/unit-19.0% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 26shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 26shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 24shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 23shared generics High-Q Pharmaceuticals196 products · 59 generics 23shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 22shared generics
Regulatory & price activity

Observed database signals

Registration numbers71
Price-history records128
Products with price history17
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date1 Jul 2024
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

57 results
Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Droncef Ceftriaxone 1 g Injection 10's 087747 PKR 5,423.83 PKR 542.38/vial/unit 10% below median
Droncef Ceftriaxone 1 g Injection 1's 087747 PKR 575.77 PKR 575.77/vial/unit Near median
Droncef Ceftriaxone 500 mg IV injection 10's 103746 PKR 2,597.96 PKR 259.80/vial/unit 17% below median
Eniqa Eflornithine 11.5% Cream 15 gm 092349 PKR 1,835.60 PKR 122.37/g No comparator
Fascar Clarithromycin 500 mg Tablet 1x10's 094146 PKR 717.48 PKR 71.75/tablet 13% below median
Fascar Clarithromycin 250 mg Tablet 1x10's 094145 PKR 430.48 PKR 43.05/tablet 8% below median
Fascar Clarithromycin 500 mg Extended-release tablet 1x5's 094147 PKR 371.29 PKR 74.26/tablet 9% below median
Fascar XL Fascar XL Clarithromycin 500 mg Extended-release tablet 1x10's 094147 PKR 692.66 PKR 69.27/tablet 15% below median
Furoxim Cefuroxime 250 mg IM/IV injection 1's 101843 PKR 44.64 PKR 44.64/vial/unit No comparator
Icunem Meropenem 500 mg Injection 1's 103719 PKR 1,755.39 PKR 1,755.39/vial/unit 16% below median
Icunem Meropenem 1 g Injection 1's 103720 PKR 3,188.94 PKR 3,188.94/vial/unit 19% below median
Kefone Cefazolin 250 mg Injection 1's 086245 PKR 71.74 PKR 71.74/vial/unit 8% below median
Kefone Cefazolin 500 mg Injection 1's 086246 PKR 107.62 PKR 107.62/vial/unit 12% below median
Kefone Cefazolin 1 g Injection 1's 086247 PKR 179.37 PKR 179.37/vial/unit 14% below median
Klindaseph Klindaseph Clindamycin 10 mg Gel 10gm 107043 PKR 366.73 PKR 36.67/g 9% below median
Lexus Levofloxacin 500 mg Tablet 1x10's 085289 PKR 746.18 PKR 74.62/tablet 5% below median
Lexus Levofloxacin 750 mg Tablet 1x10's 085290 PKR 896.84 PKR 89.68/tablet Near median
Lexus Levofloxacin 250 mg Tablet 1x10's 085288 PKR 448.43 PKR 44.84/tablet 6% below median
Lizobact Linezolid 2 mg/mL IV infusion 300ml 110936 PKR 1,114.26 PKR 3.71/mL 5% below median
Lizobact Linezolid 600 mg Tablet 2x6's 085275 PKR 4,680.83 PKR 390.07/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.